ENDPOINTS

#AACR25: GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient (MMRd) rectal tumors in a mid-stage trial who took the ...

Apr 28, 2025 - 11:37
 0
#AACR25: GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer
GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient (MMRd) rectal tumors in a mid-stage trial who took the ...
Read More

Tags:

Previous Article

8 innovative solutions for fighting food waste

Next Article

Academia needs a more honest, scientific approach to DEI

Related Posts

AstraZeneca rejoins PhRMA, two years after leaving lobby group

AstraZeneca rejoins PhRMA, two years after leaving lobb...

Apr 22, 2025  0

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche takes steps to protect itself from tariffs, while...

Apr 24, 2025  0

As the XBI suffers, Q1 shows a few comforting signs of underlying stability

As the XBI suffers, Q1 shows a few comforting signs of ...

Apr 22, 2025  0